Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration
Hye-Jung E. Chun, Pascal D. Johann, Katy Milne, et al.
Cell Reports (2019) Vol. 29, Iss. 8, pp. 2338-2354.e7
Open Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

The SWI/SNF complex in cancer — biology, biomarkers and therapy
Priya Mittal, Charles W.M. Roberts
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 7, pp. 435-448
Open Access | Times Cited: 463
An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity
Camilla Calandrini, Frans Schutgens, Rurika Oka, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 241
Molecular subgrouping of atypical teratoid/rhabdoid tumors—a reinvestigation and current consensus
Ben Ho, Pascal D. Johann, Yura Grabovska, et al.
Neuro-Oncology (2019) Vol. 22, Iss. 5, pp. 613-624
Open Access | Times Cited: 174
The epigenomics of sarcoma
Benjamin A. Nacev, Kevin B. Jones, Andrew M. Intlekofer, et al.
Nature reviews. Cancer (2020) Vol. 20, Iss. 10, pp. 608-623
Open Access | Times Cited: 168
Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours
Lars Custers, Eleonora Khabirova, Tim H. H. Coorens, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 66
SMARCB1-Deficient Cancers: Novel Molecular Insights and Therapeutic Vulnerabilities
Garrett W. Cooper, Andrew L. Hong
Cancers (2022) Vol. 14, Iss. 15, pp. 3645-3645
Open Access | Times Cited: 43
Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments
Carine Ngo, Sophie Postel‐Vinay
Biomedicines (2022) Vol. 10, Iss. 3, pp. 650-650
Open Access | Times Cited: 40
An update on the secretory functions of brown, white, and beige adipose tissue: Towards therapeutic applications
Zeinab Ghesmati, Mohsen Rashid, Shabnam Fayezi, et al.
Reviews in Endocrine and Metabolic Disorders (2023) Vol. 25, Iss. 2, pp. 279-308
Open Access | Times Cited: 37
Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases
Dörthe Holdhof, Pascal D. Johann, Michael Spohn, et al.
Acta Neuropathologica (2020) Vol. 141, Iss. 2, pp. 291-301
Open Access | Times Cited: 65
Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again
Adrienne H. Long, Daniel A. Morgenstern, Amaury Leruste, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 781-794
Closed Access | Times Cited: 35
Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment
Apoorvi Chaudhri, Gregory Lizée, Patrick Hwu, et al.
Cancer Research (2024) Vol. 84, Iss. 7, pp. 965-976
Closed Access | Times Cited: 6
Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers
Suzanne J. Forrest, Alyaa Al‐Ibraheemi, Duong Doan, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 12, pp. 2882-2890
Open Access | Times Cited: 40
Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors
Camilla Calandrini, Sander R. van Hooff, Irene Paassen, et al.
Cell Reports (2021) Vol. 36, Iss. 8, pp. 109568-109568
Open Access | Times Cited: 39
The Safety and Efficacy of Immune Checkpoint Blockade in Children, Adolescents, and Young Adults: A Systematic Review and Meta-Analysis
Pedro Cotta Abrahão Reis, João Evangelista Ponte Conrado, Mariana Macambira Noronha, et al.
EJC Paediatric Oncology (2025), pp. 100215-100215
Open Access
Hallmark discoveries in the biology of non-Wilms tumour childhood kidney cancers
Daniela Perotti, Maureen J. O’Sullivan, Amy L. Walz, et al.
Nature Reviews Urology (2025)
Closed Access
What Have We Learnt from the Recent Multimodal Managements of Young Patients with ATRT?
Sylvia Cheng, Chantel Cacciotti, Carol L. S. Yan, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1116-1116
Open Access
SMARCB1 loss interacts with neuronal differentiation state to block maturation and impact cell stability
Alison D. Parisian, Tomoyuki Koga, Shunichiro Miki, et al.
Genes & Development (2020) Vol. 34, Iss. 19-20, pp. 1316-1329
Open Access | Times Cited: 36
Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors
Karolina Nemes, Pascal D. Johann, Stefanie Tüchert, et al.
Cancer Management and Research (2022) Vol. Volume 14, pp. 479-498
Open Access | Times Cited: 20
Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors
Yukitomo Ishi, Yongzhan Zhang, Ali Zhang, et al.
Molecular Cancer Therapeutics (2022) Vol. 21, Iss. 5, pp. 715-726
Open Access | Times Cited: 19
Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors
Cinzia Lanzi, Noemi Arrighetti, Sandro Pasquali, et al.
Biochemical Pharmacology (2023) Vol. 215, pp. 115727-115727
Closed Access | Times Cited: 12
DNA methylation-based age estimation in pediatric healthy tissues and brain tumors
Teresia Kling, Anna Wenger, Helena Carén
Aging (2020) Vol. 12, Iss. 21, pp. 21037-21056
Open Access | Times Cited: 30
Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury
Laura M. Williamson, Craig M. Rive, Daniela Di Francesco, et al.
npj Precision Oncology (2021) Vol. 5, Iss. 1
Open Access | Times Cited: 25
DIMEimmune: Robust estimation of infiltrating lymphocytes in CNS tumors from DNA methylation profiles
Sepehr Safaei, Malte Mohme, Judith Niesen, et al.
OncoImmunology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 23
Children's Oncology Group's 2023 blueprint for research: Renal tumors
James I. Geller, Andrew L. Hong, Kelly Vallance, et al.
Pediatric Blood & Cancer (2023) Vol. 70, Iss. S6
Open Access | Times Cited: 10
SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors
Ning Qing Liu, Irene Paassen, Lars Custers, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top